Navigation Links
Research increases possibilities of personalizing treatment of infant osteosarcoma
Date:2/18/2009

This release is available in Spanish.

A team of specialists at the University Hospital of Navarra have revealed the existence of genetic variants that have greater resistance to a specific treatment and a greater toxicity of the pharmaceutical drug in some child patients affected by osteosarcoma. The team investigated the mechanisms of the illness in order to obtain a personalised therapeutic treatment in the future.

In concrete, the research focused on the analysis of the side effects due to the administration of methotrexate in a hundred of such patients. This medication was chosen because, to treat infant osteosarcoma, high levels of dosage are administered in terms of grammes being a multiplication by a thousand of the methotrexate dosage given in other, frequently-occurring cancer diseases, such as leukaemia. Such high dosage can cause very important toxic effects, and thus the need to know the genetic mechanisms bearing on the resistance to treatment and the tolerance to the pharmaceutical drug, explained Doctor Ana Patio, main research author of the article to be published in the scientific journal, The Journal of Pediatrics, the second with the greatest world impact in its speciality.

Notable amongst the team participating in the study is the biologist/biochemist Doctor Marta Zalacain, who suffered an osteosarcoma when she was 11 years old, and for which she was treated and cured at the University Hospital by a team led by Dr Sierrasesmaga, the group with which she is currently working on the mechanisms of this illness.

Large group of patients

The work was drawn up for a group of 100 patients, one of the largest in the world, given the scant incidence of the illness (estimated annually at one person per million inhabitants). To give an idea of the importance of the group studied by Doctor Sierrasesmaga, Director of the Department of Paediatrics at the University Hospital of Navarra and specialist in infant cancer, it can be pointed out that, in all of Spain, 45 child patients suffering from osteosarcoma are detected on average each year there. Thus, the hundred patients under study is a very large number and, moreover, it is a particularly exceptional study in that it provides access to its genetic material, to the tumour material and to all the complete clinical data of the hundred patients studied. 70% survival rate at the University Hospital

The survival prognosis of infant patients with osteosarcoma at the University Hospital of Navarra, including the metastasic ones, is about 70%, compared to the 60-65% average at other international centres of reference in the treatment of this oncological illness. As a consequence of this high survival rate, added Doctor Patio, the concern is also with the quality of life of survivors. The goal of the research work is focusing on finding therapeutic tools that minimise the toxic effects of treatment and maximise the therapeutic effects.

Observing the genetic variants of the genes involved in the methotrexate metabolism, they have shown that some of these variants are associated with different toxicity of the pharmaceutical drug and, accordingly, obtain better or worse therapeutic effects, stated the specialist. In concrete, the research team studied genetic variants of children in which the tumours prove themselves to be intrinsically resistant to the medical treatment. These are the patients for whom it is necessary to administer high levels of methotrexate in order to obtain a good response.

To obtain these data, the researchers were able to work closely with the Department of Pharmacology at the University Hospital of Navarra, where the kinetics of the drug in the blood was analysed for each of the patients in the study. In this way, explained Ms Patio, they monitored the children to see if they had eliminated the amount of drug left over after the required therapeutic effect had taken effect, given that, otherwise, significant toxicity could be caused.

As a result of the research, the specialists have identified the genetic variant responsible for this greater methotrexate toxicity affecting certain children with osteosarcoma. Although, for the moment, the genotype has not yet changed the treatment of the illness, the aim is to gradually intensify this type of genetic study through analysis the results of which can be readily obtained - in a matter of 90 minutes. In this way, what is involved is the location of new genes and thus being able to adjust the dosage of the various pharmaceutical drugs that we administer, in order to maximise the therapeutic results and minimise the toxicity in each one of the patients treated, concluded the researcher.


'/>"/>

Contact: Oihane Lakar
oihane@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimers Disease
2. The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc.
3. Apple's iPod Touch Joins the iPhone as a Stuttering Therapy Tool At Hollins Communications Research Institute
4. Rice Universitys Baker Institute experts available to discuss stem cell research, recommendations
5. eResearchTechnology, Inc. to Announce Fourth Quarter and Full Year 2008 Results on February 26, 2009
6. National Pharmaceutical Council on Economic Stimulus Package: Comparative Effectiveness Research Funding Should Target Improvements in Quality of Patient Care
7. OHSU vaccine research targets HIV in the slower, early stage of infection
8. American Association for Cancer Research lauds Senator Arlen Specter
9. In flurry of studies, researcher details role of apples in inhibiting breast cancer
10. LSUHSC research may benefit diabetes by increasing understanding of how to control islet cell growth
11. Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... ZyDoc , a New York-based ... Data Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” ... comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital and ... with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group ... said, “CURE Media Group is honored to team up with Upstage Lung Cancer in ...
(Date:12/8/2016)... ... 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing ... wellness program, at their world headquarters of Omni La Costa Resort & Spa in ... anyone seeking weight loss, personal development, a healthy lifestyle, or mental and physical healing. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... ... ... California Senate Bill (SB) 863, signed into law in 2012, may have ... according to CompScope™ Medical Benchmarks for California, 17th Edition , a study by ... payments per claim in California decreased 4 percent in 2013 and then 3 percent ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 Dignitana, a world leader ... with Boa® Technology, creator of the award-winning, patented Boa® ... use with the DigniCap® scalp cooling system. DigniCap® was ... December 2015, and is the first medical scalp cooling ... scalp cooling system features a patented tight-fitting silicone cooling ...
(Date:12/8/2016)... in the United States will continue in 2017, say ... December 2016 Semiannual Economic Forecast. Expectations are for a ... as indicated in the monthly ISM ® ... is optimistic about growth in 2017, with revenues expected ... sector indicates that 14 of its industries will see ...
(Date:12/8/2016)... 8, 2016 According to a new market research ... Fetal), Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, ... the global market, in terms of value, is projected to reach 12.14 ... of 18.0% during the forecast period. Continue ... ...
Breaking Medicine Technology: